Also found in: Wikipedia.
RVORetinal Vein Occlusion (eye condition)
RVORechtsverordnung (German: legal decree)
RVORecycled Vegetable Oil
RVORoyal Victorian Order (UK)
RVORemediation Venture Office (US Army)
RVOReturn Value Optimization
RVORadio Val d'Or (French radio station)
RVORussian Virtual Observatory
RVORegional Veterinary Officer (UK)
RVORacing Vaunage Organisation (French car racing organization)
RVOReciprocal Velocity Obstacle
RVORequest for Variation Order (prior to VO approval)
RVORunway Visibility by Observer
RVOReader Voice Over
RVORepresentatieve Vakorganisaties
RVORemote Virtual Office (Citrix Systems computing)
RVORhonda's Virtual Office (Cincinnati, OH)
References in periodicals archive ?
Earlier studies have shown the correlation between RVO and the risk factors and more studies are necessary to know risk factors better in this disease to determine a specific protocol for the treatment and prophylaxis of RVO.
Sudden blurring or vision loss in all or part of one eye is common with RVO, although loss of vision can develop over a long period of time.
An absence of a b-wave on electroretinogram (ERG) also confirms that the RVO is ischaemic5
We speculated that OHS was the cause of polycythemia, papilledema, and RVO in this patient, and effective experimental treatment further confirmed our conjecture.
Results: In all follow-up months, there was a significant increase in BCVA in all RVO cases and in superotemporal BRVO cases after the first injection of ranibizumab.
As RVO moves from our research and development stage into commercialization, it's more important than ever to have someone with John's background at the helm.
The theme of patient satisfaction was revisited by RVO Vice President of Research & Development Keith Holliday, Ph.
MATERIALS: Patients attending our OPD at Government General Hospital, Guntur who are diagnosed to have RVO.
M2 EQUITYBITES-May 23, 2014-Lanthio Pharma receives Innovation Credit loan from RVO
It is particularly important for patients suffering from branch retinal vein occlusion, the most common form of RVO, affecting five people in every 1,000 over the age of 30, where no licensed pharmacological treatment is available on the NHS in Scotland.
M2 PHARMA-May 23, 2014-Lanthio Pharma receives Innovation Credit loan from RVO
Until the market entry of Lucentis (ranibizumab) in 2006, the RVO therapeutics market was growing at a lower rate.